7/102 sources · 2 publishersUpdated Oct 23, 11:57 UTC
Bristol Myers Squibb and SystImmune report 59% reduction in disease progression for breast cancer drug iza‑bren
Bristol Myers Squibb and partner SystImmune announced that their bispecific ADC iza‑bren cut the risk of disease progression or death by 59% versus chemotherapy in a Phase 3 trial of HR+/HER2‑negative breast cancer. Median progression‑free survival was 8.2 months for iza‑bren compared with 4.0 months for chemotherapy. The study enrolled 383 patients and showed a confirmed objective response rate of 40.5% versus 20.2% for chemotherapy.
Why it matters
The trial’s positive efficacy and manageable safety profile could expand BMY’s oncology pipeline and support future revenue growth, according to the companies’ press release.
Key facts
- 1The Phase 3 PANKU‑Breast01 trial enrolled 383 patients with unresectable locally advanced, recurrent or metastatic HR+/HER2‑negative breast cancer. investing.com
- 2Iza‑bren reduced the risk of disease progression or death by 59% compared with chemotherapy (hazard ratio 0.41, 95% CI 0.33‑0.53, p < 0.0001). investing.com
- 3Median progression‑free survival was 8.2 months for iza‑bren versus 4.0 months for chemotherapy. investing.com
- 4Confirmed objective response rate was 40.5% with iza‑bren and 20.2% with chemotherapy. investing.com
- 5Median duration of response was 6.9 months for iza‑bren and 4.2 months for chemotherapy. investing.com
- 6Grade 3 or higher treatment‑related adverse events were mainly hematologic; 1.6% of patients discontinued iza‑bren due to adverse events. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.